[go: up one dir, main page]

MX2019005497A - Moleculas de pmhc de clase ii recombinantes. - Google Patents

Moleculas de pmhc de clase ii recombinantes.

Info

Publication number
MX2019005497A
MX2019005497A MX2019005497A MX2019005497A MX2019005497A MX 2019005497 A MX2019005497 A MX 2019005497A MX 2019005497 A MX2019005497 A MX 2019005497A MX 2019005497 A MX2019005497 A MX 2019005497A MX 2019005497 A MX2019005497 A MX 2019005497A
Authority
MX
Mexico
Prior art keywords
polypeptide
domain
mhc class
molecules
combination
Prior art date
Application number
MX2019005497A
Other languages
English (en)
Inventor
Santamaria Pedro
Original Assignee
Uti Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uti Lp filed Critical Uti Lp
Publication of MX2019005497A publication Critical patent/MX2019005497A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Ceramic Engineering (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen en este documento heterodímeros que contienen por lo menos un primer polipéptido y por lo menos un segundo polipéptido, en el que el primer polipéptido y el segundo polipéptido se encuentran en una interfaz, en el que la interfaz del primer polipéptido contiene una protuberancia diseñada por ingeniería que se puede posicionar en una cavidad diseñada por ingeniería en la interfaz del segundo polipéptido; y (i) el primer polipéptido contiene un dominio a1 de MHC de clase II, un dominio a2 de MHC de clase II, o una combinación de los mismos; y el segundo polipéptido comprende un dominio ß1 de MHC de clase II, un dominio ß2 de MHC de clase II, o una combinación de los mismos; o (ii) el primer polipéptido contiene un dominio ß1 de MHC de clase II, un dominio ß2 de MHC de clase II, o una combinación de los mismos; y el segundo polipéptido comprende un dominio a1 de MHC de clase II, un dominio a2 de MHC de clase II, o una combinación de los mismos.
MX2019005497A 2016-11-09 2017-11-08 Moleculas de pmhc de clase ii recombinantes. MX2019005497A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662419947P 2016-11-09 2016-11-09
PCT/IB2017/001508 WO2018087597A1 (en) 2016-11-09 2017-11-08 Recombinant pmhc class ii molecules

Publications (1)

Publication Number Publication Date
MX2019005497A true MX2019005497A (es) 2019-11-18

Family

ID=62065064

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005497A MX2019005497A (es) 2016-11-09 2017-11-08 Moleculas de pmhc de clase ii recombinantes.

Country Status (16)

Country Link
US (2) US20180127481A1 (es)
EP (2) EP4613336A3 (es)
JP (1) JP2020500015A (es)
KR (2) KR102646495B1 (es)
CN (1) CN110291111A (es)
AU (2) AU2017357865B2 (es)
BR (1) BR112019009477A2 (es)
CA (1) CA3042615A1 (es)
CO (1) CO2019004751A2 (es)
DK (1) DK3538559T3 (es)
ES (1) ES3035837T3 (es)
IL (1) IL266391A (es)
MX (1) MX2019005497A (es)
NZ (1) NZ753596A (es)
SG (1) SG10201913956RA (es)
WO (1) WO2018087597A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
SG11201603487YA (en) 2013-11-04 2016-05-30 Uti Limited Partnership Methods and compositions for sustained immunotherapy
WO2016198932A2 (en) 2015-05-06 2016-12-15 Uti Limited Partnership Nanoparticle compositions for sustained therapy
PT3558339T (pt) 2016-12-22 2024-03-15 Cue Biopharma Inc Polipeptídeos multiméricos moduladores de células t e métodos de utilização dos mesmos
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CA3054955A1 (en) 2017-03-15 2018-09-20 Cue Biopharma, Inc. Methods for modulating an immune response
US12397038B2 (en) 2017-11-29 2025-08-26 Uti Limited Partnership Ubiquitous antigens for treatment of autoimmune or inflammatory diseases
EP3737689A4 (en) 2018-01-09 2021-12-01 Cue Biopharma, Inc. MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE
CN113164573B (zh) * 2018-10-05 2024-05-31 俄勒冈健康科学大学 包含修饰的MHC II类DRα1结构域的重组多肽及其应用方法
JP7691927B2 (ja) * 2019-03-06 2025-06-12 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節抗原提示ポリペプチド及びその使用方法
EP3935080A4 (en) * 2019-03-06 2023-04-05 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
WO2020181273A1 (en) * 2019-03-06 2020-09-10 Cue Biopharma, Inc. Antigen-presenting polypeptides with chemical conjugation sites and methods of use thereof
KR20220044683A (ko) * 2019-08-09 2022-04-11 프라운호퍼 게젤샤프트 쭈르 푀르데룽 데어 안겐반텐 포르슝 에. 베. 관절염 치료를 위한 hla-dr/cii 펩티드 복합체
WO2021035049A1 (en) * 2019-08-21 2021-02-25 Uti Limited Partnership Improved recombinant pmhc molecules
CA3163549A1 (en) * 2019-12-02 2021-06-10 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
CN111808170A (zh) * 2020-06-29 2020-10-23 江苏为真生物医药技术股份有限公司 多肽、hla-dr蛋白及其制备方法和应用
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
EP4577225A2 (en) * 2022-08-26 2025-07-02 The Board of Trustees of the Leland Stanford Junior University Chimeric cytokine receptors and methods of use
WO2025021112A1 (zh) * 2023-07-24 2025-01-30 佳吾益(北京)科技有限公司 开发mhc新抗原的工程化细胞
WO2025111562A1 (en) * 2023-11-22 2025-05-30 Cue Biopharma, Inc. Mhc class ii protein complexes

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4367110A (en) 1979-07-02 1983-01-04 Toppan Printing Co. Decorative laminate and a manufacturing method therefor
US4452901A (en) 1980-03-20 1984-06-05 Ciba-Geigy Corporation Electrophoretically transferring electropherograms to nitrocellulose sheets for immuno-assays
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
GB2097032B (en) 1981-04-22 1984-09-19 Teron International Urban Dev A combined ceiling air and services distribution system mechanical chasse and structural roof member
US4818542A (en) 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US6103379A (en) 1994-10-06 2000-08-15 Bar-Ilan University Process for the preparation of microspheres and microspheres made thereby
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DE69730038T2 (de) * 1996-08-16 2004-11-25 The President And Fellows Of Harvard College, Cambridge Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen
WO1999056763A1 (en) 1998-05-07 1999-11-11 The Regents Of The University Of California Use of neglected target tissue antigens in modulation of immune responses
US6150022A (en) 1998-12-07 2000-11-21 Flex Products, Inc. Bright metal flake based pigments
US6651655B1 (en) 2000-01-18 2003-11-25 Quadrant Technologies Limited Inhaled vaccines
KR100379250B1 (ko) 2000-12-04 2003-04-08 한국과학기술연구원 나노 단위 크기의 금속 입자가 함유된 고분자 복합 소재및 그 제조 방법
US20120083008A1 (en) * 2004-07-06 2012-04-05 Marshall Christopher P Methods for obtaining molecules with reduced immunogenicity
US20140105980A1 (en) * 2012-10-11 2014-04-17 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
CA2743590A1 (en) 2008-11-12 2010-05-20 Yeda Research And Development Co. Ltd. Diagnosis of multiple sclerosis
GB201002730D0 (en) * 2010-02-18 2010-04-07 Uni I Oslo Product
KR101468769B1 (ko) * 2011-03-04 2014-12-08 사회복지법인 삼성생명공익재단 갑상선암 특이적 자성나노입자 복합체 및 이의 용도
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
WO2014096015A1 (en) * 2012-12-21 2014-06-26 F. Hoffmann-La Roche Ag Disulfide-linked multivalent mhc class i comprising multi-function proteins
EP2986807B1 (en) * 2013-08-31 2018-04-04 Halliburton Energy Services, Inc. Deflector assembly for a lateral wellbore
SG11201603487YA (en) 2013-11-04 2016-05-30 Uti Limited Partnership Methods and compositions for sustained immunotherapy
KR102825102B1 (ko) * 2014-12-24 2025-06-26 넥스이뮨, 인크. 면역요법을 위한 나노입자 조성물 및 방법
WO2016198932A2 (en) * 2015-05-06 2016-12-15 Uti Limited Partnership Nanoparticle compositions for sustained therapy

Also Published As

Publication number Publication date
EP3538559A4 (en) 2020-06-24
NZ753596A (en) 2025-10-31
EP3538559A1 (en) 2019-09-18
US20250051420A1 (en) 2025-02-13
SG10201913956RA (en) 2020-03-30
KR20240036138A (ko) 2024-03-19
EP4613336A3 (en) 2025-12-03
RU2019114627A3 (es) 2021-04-02
US20180127481A1 (en) 2018-05-10
EP3538559B1 (en) 2025-04-09
JP2020500015A (ja) 2020-01-09
WO2018087597A1 (en) 2018-05-17
IL266391A (en) 2019-06-30
EP4613336A2 (en) 2025-09-10
AU2017357865A1 (en) 2019-05-23
KR102646495B1 (ko) 2024-03-12
BR112019009477A2 (pt) 2019-07-30
CO2019004751A2 (es) 2019-05-21
RU2019114627A (ru) 2020-12-10
ES3035837T3 (en) 2025-09-10
KR20190104320A (ko) 2019-09-09
DK3538559T3 (da) 2025-07-14
AU2017357865B2 (en) 2024-10-31
CN110291111A (zh) 2019-09-27
CA3042615A1 (en) 2018-05-17
AU2025200608A1 (en) 2025-04-03

Similar Documents

Publication Publication Date Title
MX2019005497A (es) Moleculas de pmhc de clase ii recombinantes.
CO2019005966A2 (es) Esteroides y conjugados de proteínas de los mismos
TWD198103S (zh) 注射裝置的帽蓋（六）
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
TWD192290S (zh) 鞋墊
TWD179356S (zh) 自動注射裝置之部分
CA2921232A1 (en) Adeno-associated virus factor viii vectors
TWD184351S (zh) 醫療器材之部分
TWD166194S (zh) 車輛頭燈（二）
TWD168204S (zh) 車頭燈（一）
BR112019008162A2 (pt) método para executar uma liquidação e sistema para executar uma liquidação
TWD192214S (zh) 電子裝置
BR112016000565A2 (pt) polipeptídeo cíclico, derivado ou análogo do mesmo e seu uso modulador alostérico, composição farmacêutica, processo para produzir a mesma
PH12021550289A1 (en) Ox40-binding polypeptides and uses thereof
MX2017008660A (es) Polipeptidos enlazados a il-17a.
MX2019008549A (es) Anticuerpos dirigidos a los huesos.
UY35463A (es) Formulaciones de polipéptido fc-factor ix.
BR112017011433A2 (pt) roda abrasiva não tecida com uma camada de barreira à umidade
BR112018016487A2 (pt) processo para produzir um compósito de polímero/fibra termoformável compósito de polímero/fibra termoformável, processo para produzir uma moldagem de polímero/fibra, moldagem de polímero/fibra, e, uso de um compósito de polímero/fibra termoformável e de uma moldagem de polímero/fibra.
UY35412A (es) Formulaciones de fviii recombinante
TWD186594S (zh) 音頻切換器之部分
TWD187080S (zh) 自動注射器之部分
MX384037B (es) Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso.
PH12020551582A1 (en) Lfa3 variants and compositions and uses thereof
TWD191609S (zh) 電動車